Mineralocorticoid receptor–Glucocorticoid receptor heterodimer (GR–MR heterodimer)

The Mineralocorticoid receptor–Glucocorticoid receptor (GR–MR) heterodimer is a functional transcriptional complex formed by the physical association of the Mineralocorticoid Receptor (NR3C2) and the Glucocorticoid Receptor (NR3C1) (UniProt P08235, P04150). This heterodimerization occurs primarily in tissues where both receptors are co-expressed, such as the hippocampus, heart, and kidneys, and serves as a critical mechanism for integrating physiological signals from aldosterone and cortisol (PubMed: 11435611). The GR–MR heterodimer exhibits unique DNA-binding affinities and co-regulator recruitment patterns that differ from their respective homodimers, allowing for highly nuanced control over genes involved in fluid balance, blood pressure, and stress adaptation (PubMed: 7932705). Dysregulation of the GR–MR balance or the stability of their interface is implicated in the progression of cardiovascular diseases like heart failure and hypertension, as well as neuropsychiatric conditions such as major depression (PubMed: 25635988). Pharmacological targeting of this interface, either through direct disruption or via selective ligands that favor specific dimeric configurations, represents a promising strategy for developing more precise therapies with fewer off-target effects. Currently, drugs such as finerenone and various glucocorticoid modulators influence the activity of this complex by binding to the individual receptor subunits and altering the dimer's functional state (PubMed: 30104256).

Other names

MR–GR complexNR3C2–NR3C1 heterodimerCorticoid receptor heterodimerMineralocorticoid receptor via GR–MR heterodimer interface

Modulation of gene transcription by altering the stability, DNA-binding affinity, and co-regulator recruitment of the GR–MR heterodimeric complex through ligand binding at the respective receptor subunits (PubMed: 30104256).